Ticker: PRAX

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Here's an overview of the company's performance in the second quarter of 2025, highlighting key aspects of their income stateme...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported its Q1 2025 financial results, continuing its path as a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Key Financial Metrics: Net loss for Q1 2025: $69.3 million, compared...